

## Product datasheet for **SR308982**

### **Bcl2 Binding component 3 (BBC3) Human siRNA Oligo Duplex (Locus ID 27113)**

#### **Product data:**

<b>Product Type:</b>	siRNA Oligo Duplexes
<b>Purity:</b>	HPLC purified
<b>Quality Control:</b>	Tested by ESI-MS
<b>Sequences:</b>	Available with shipment
<b>Stability:</b>	One year from date of shipment when stored at -20°C.
<b># of transfections:</b>	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
<b>Note:</b>	Single siRNA duplex (10nmol) can be ordered.
<b>RefSeq:</b>	<a href="#">NM_001127240</a> , <a href="#">NM_001127241</a> , <a href="#">NM_001127242</a> , <a href="#">NM_014417</a>
<b>UniProt ID:</b>	<a href="#">Q9BXH1</a>
<b>Synonyms:</b>	JFY-1; JFY1; PUMA
<b>Components:</b>	BBC3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 27113) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml
<b>Summary:</b>	This gene encodes a member of the BCL-2 family of proteins. This family member belongs to the BH3-only pro-apoptotic subclass. The protein cooperates with direct activator proteins to induce mitochondrial outer membrane permeabilization and apoptosis. It can bind to anti-apoptotic Bcl-2 family members to induce mitochondrial dysfunction and caspase activation. Because of its pro-apoptotic role, this gene is a potential drug target for cancer therapy and for tissue injury. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011]



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).